Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19 ...

FDA Breakthrough designation supports development of a point-of-care test for detecting folate receptor autoantibodies ...

GRIN Therapeutics begins patient dosing in global phase 3 Beeline trial of investigational radiprodil for GRINRelated neurodevelopmental disorder: New York Monday, January 12, 202 ...

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales ...

Cancer immunotherapy has already transformed treatment for some patients, yet too often the body’s defenders stall out before ...

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for ...

Using a blend of computer modeling, structural and cell-based studies, scientists at The Wertheim UF Scripps Institute have ...

“Orforglipron and retatrutide from Eli Lilly exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior ...

Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 ...

InflaRx had been pursuing development of vilobelimab in other indications beyond COVID, but the company’s hopes for the asset ...

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 ...

In a study published in Nature Immunology on January 6, a research team led by Prof. Qian Youcun from the Shanghai Institute ...